PubMed Health⌕ Search

Biomedical subjects

U R Osarogiagbon

Publications and source records attributed to U R Osarogiagbon.

2 recordsLinked to original sources

Reperfusion injury pathophysiology in sickle transgenic mice.

Reperfusion of tissues after interruption of their vascular supply causes free-radical generation that leads to tissue damage, a scenario referred to as "reperfusion injury." Because sickle disease involves repeated transient ischemic episodes, we sought evidence for excessive free-radical generation in sickle transgenic mice. Compared with normal mice, sickle mice at ambient air had a higher ethane excretion (marker of lipid peroxidation) and greater conversion of salicylic acid to 2,3-dihydroxybenzoic acid (marker of hydroxyl radical generation). During hypoxia (11% O(2)), only sickle mice converted tissue xanthine dehydrogenase to oxidase. Only the sickle mice exhibited a further increase in ethane excretion during restitution of normal oxygen tension after 2 hours of hypoxia. Only the sickle mice showed abnormal activation of nuclear factor-kappaB after exposure to hypoxia-reoxygenation. Allopurinol, a potential therapeutic agent, decreased ethane excretion in the sickle mice. Thus, sickle transgenic mice exhibit biochemical footprints consistent with excessive free-radical generation even at ambient air and following a transient induction of enhanced sickling. We suggest that reperfusion injury physiology may contribute to the evolution of the chronic organ damage characteristic of sickle cell disease. If so, novel therapeutic approaches might be of value.

Allopurinol↗

Chronic myelogenous leukemia.

Over the past year, new information has been reported on the biology and treatment of chronic myelogenous leukemia (CML). Chronic myelogenous leukemia is characterized by the breakpoint cluster region (BCR-ABL) chimeric gene, the product of which is p210BCR-ABL, a tyrosine kinase that gives hematopoietic cells the characteristics of excessive proliferation, resistance to physiologic apoptotic signals, and resistance to chemotherapy. Recently, investigators have attempted to 1) elucidate the mechanisms by which the BCR-ABL gene and its product initiate and maintain the malignant phenotype, 2) improve the use of the BCR-ABL gene as a diagnostic marker of disease, and 3) inhibit the expression of this gene as a therapeutic maneuver. Other investigators have tried to explain interferon's mechanism of action in the treatment of CML and to improve the safety and applicability of stem cell transplantation (SCT) as a therapy for CML.

Animals↗